Changchun Hi-Tech announced that Jinsai Pharmaceutical, a holding subsidiary of the company, received the “Notice of Acceptance” approved and issued by the State Drug Administration. Jinsai Pharmaceutical's application for registration of domestically produced drug registration for GenSci 117 inhalation powder was accepted. The acceptance number is CXHL2601358, with a specification of 60 mg/bottle. The indication is idiopathic pulmonary fibrosis. GenSci117 is an innovative chemical class 1 drug intended for the treatment of idiopathic pulmonary fibrosis.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.